Top

Breast Cancer

Published in:

01-07-2011 | Original Article

Preoperative and intraoperative predictors of positive margins after breast-conserving surgery: a retrospective review

Authors: Payam Saadai, Manijeh Moezzi, Tehillah Menes

Published in: Breast Cancer | Issue 3/2011

Abstract

Background

Breast-conserving therapy is an established treatment for early breast cancer. Current practice mandates reoperation for positive margins. Presently most patients are brought to the operating room with a diagnosis of breast cancer made on core biopsy. Preoperative and intraoperative predictors of margin status are needed.

Methods

A retrospective review of patients with adenocarcinoma proven on core biopsy undergoing breast-conserving surgery between 2000 and 2007. Clinical, radiographic, pathological, and operative data were collected. These were correlated with margin status on excision.

Results

One hundred twenty-seven patients met the inclusion criteria. Predictors of positive margins at lumpectomy were younger age, larger size on imaging, calcifications on mammography, multifocality, ductal carcinoma in situ (DCIS) or necrosis on core biopsy, and close margins on specimen films.

Conclusions

In the era of preoperative diagnosis of breast cancer with core biopsy, several pre- and intraoperative predictors of positive margins are identified that can aid the surgeon in surgical planning.

Fisher B, Anderson S, Redmond CK, Wolmark N, Wickerham DL, Cronin WM. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med. 1995;333(22):1456–61.PubMedCrossRef

Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347(16):1227–32.PubMedCrossRef

Poggi MM, Danforth DN, Sciuto LC, Smith SL, Steinberg SM, Liewehr DJ, et al. Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial. Cancer. 2003;98(4):697–702.PubMedCrossRef

Boyages J, Delaney G, Taylor R. Predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. Cancer. 1999;85(3):616–28.PubMedCrossRef

Horst KC, Smitt MC, Goffinet DR, Carlson RW. Predictors of local recurrence after breast-conservation therapy. Clin Breast Cancer. 2005;5(6):425–38.PubMedCrossRef

Mechera R, Viehl CT, Oertli D. Factors predicting in-breast tumor recurrence after breast-conserving surgery. Breast Cancer Res Treat. 2008.

Aziz D, Rawlinson E, Narod SA, Sun P, Lickley HL, McCready DR, et al. The role of reexcision for positive margins in optimizing local disease control after breast-conserving surgery for cancer. Breast J. 2006;12(4):331–7.PubMedCrossRef

Kurniawan ED, Wong MH, Windle I, Rose A, Mou A, Buchanan M, et al. Predictors of surgical margin status in breast-conserving surgery within a breast screening program. Ann Surg Oncol. 2008;15(9):2542–9.PubMedCrossRef

Lovrics PJ, Cornacchi SD, Farrokhyar F, Garnett A, Chen V, Franic S, et al. The relationship between surgical factors and margin status after breast-conservation surgery for early stage breast cancer. Am J Surg. 2009;197(6):740–6.PubMedCrossRef

10.

Bani MR, Lux MP, Heusinger K, Wenkel E, Magener A, Schulz-Wendtland R, et al. Factors correlating with reexcision after breast-conserving therapy. Eur J Surg Oncol. 2009;35(1):32–7.PubMed

11.

Smitt MC, Horst K. Association of clinical and pathologic variables with lumpectomy surgical margin status after preoperative diagnosis or excisional biopsy of invasive breast cancer. Ann Surg Oncol. 2007;14(3):1040–4.PubMedCrossRef

12.

Dillon MF, Maguire AA, McDermott EW, Myers C, Hill AD, O’Doherty A, et al. Needle core biopsy characteristics identify patients at risk of compromised margins in breast conservation surgery. Mod Pathol. 2008;21(1):39–45.PubMedCrossRef

13.

Miller AR, Brandao G, Prihoda TJ, Hill C, Cruz AB Jr, Yeh IT. Positive margins following surgical resection of breast carcinoma: analysis of pathologic correlates. J Surg Oncol. 2004;86(3):134–40.PubMedCrossRef

14.

Mai KT, Chaudhuri M, Perkins DG, Mirsky D. Resection margin status in lumpectomy specimens for duct carcinoma of the breast: correlation with core biopsy and mammographic findings. J Surg Oncol. 2001;78(3):189–93.PubMedCrossRef

15.

Jimenez RE, Bongers S, Bouwman D, Segal M, Visscher DW. Clinicopathologic significance of ductal carcinoma in situ in breast core needle biopsies with invasive cancer. Am J Surg Pathol. 2000;24(1):123–8.PubMedCrossRef

16.

Kollias J, Gill PG, Beamond B, Rossi H, Langlois S, Vernon-Roberts E. Clinical and radiological predictors of complete excision in breast-conserving surgery for primary breast cancer. Aust NZ J Surg. 1998;68(10):702–6.CrossRef

17.

Dener C, Inan A, Sen M, Demirci S. Interoperative frozen section for margin assessment in breast conserving energy. Scand J Surg. 2009;98(1):34–40.PubMed

18.

Olson TP, Harter J, Munoz A, Mahvi DM, Breslin T. Frozen section analysis for intraoperative margin assessment during breast-conserving surgery results in low rates of re-excision and local recurrence. Ann Surg Oncol. 2007;14(10):2953–60.PubMedCrossRef

19.

Fleming FJ, Hill AD, Mc Dermott EW, O’Doherty A, O’Higgins NJ, Quinn CM. Intraoperative margin assessment and re-excision rate in breast conserving surgery. Eur J Surg Oncol. 2004;30(3):233–7.PubMed

20.

Lee JM, Orel SG, Czerniecki BJ, Solin LJ, Schnall MD. MRI before reexcision surgery in patients with breast cancer. AJR Am J Roentgenol. 2004;182(2):473–80.PubMed

21.

Jacobson AF, Asad J, Boolbol SK, Osborne MP, Boachie-Adjei K, Feldman SM. Do additional shaved margins at the time of lumpectomy eliminate the need for re-excision? Am J Surgery. 2008;196(4):556–8.

Title: Preoperative and intraoperative predictors of positive margins after breast-conserving surgery: a retrospective review
Authors: Payam Saadai
Manijeh Moezzi
Tehillah Menes
Publication date: 01-07-2011
Publisher: Springer Japan
Published in: Breast Cancer / Issue 3/2011
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI: https://doi.org/10.1007/s12282-011-0262-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2011

Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy

Radiographic features for triple negative ductal carcinoma in situ of the breast

Mammography and ultrasound features of triple-negative breast cancer

A patient presenting nasal septum perforation during bevacizumab-containing chemotherapy for advanced breast cancer

Incidence of chemotherapy-induced amenorrhea in premenopausal patients with breast cancer following adjuvant anthracycline and taxane

MR imaging of triple-negative breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer